Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 st
3 hours ago
- #Eribulin
- #Triple-negative breast cancer
- #Neoadjuvant chemotherapy
- The study investigated long-term outcomes of eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer (TNBC) patients stratified by homologous recombination deficiency (HRD) and germline BRCA mutation (gBRCAm) status.
- Patients were divided into groups based on HRD status and age, with different treatment regimens assigned to each group.
- Results showed significantly better prognosis in patients who achieved pathological complete response (pCR) after neoadjuvant therapy, with 5-year invasive disease-free survival (IDFS) and overall survival (OS) rates of 95% and 100%, respectively.
- Exploratory analysis suggested better OS trends in patients with higher baseline lymphocyte counts (LC ≥ 1500/mm3) and lower neutrophil-to-lymphocyte ratios (NLR < 3).
- The findings support the development of eribulin-based neoadjuvant chemotherapy for selected TNBC patients and highlight potential biomarkers for clinical prediction models.